Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.42 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | IL2 | P60568 | 1/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027378 | 0.84 | IL2 (0.44) | P2RX7LTA4HHPGDSPIN1IL2 | |
| SCHEMBL5028506 | 0.78 | P2RX7 (0.45) | P2RX7LTA4HTRPM4IL2 | |
| Hydrochloric Acid SCHEMBL5033017 | 0.75 | P2RX7 (0.41) | P2RX7LTA4HIL2 | |
| SCHEMBL28907410 | 0.75 | ALK (0.49) | P2RX7ALKCAMKK2 | |
| SCHEMBL18930006 | 0.75 | NPC1 (0.46) | P2RX7LTA4HHPGDSIL2 | |
| SCHEMBL8628488 | 0.74 | HPGDS (0.51) | P2RX7LTA4HHPGDSIL2HDAC4 | |
| SCHEMBL13104973 | 0.72 | LTA4H (0.41) | P2RX7LTA4HHPGDSTRPM4IL2 | |
| SCHEMBL377220 | 0.71 | IL2 (0.46) | P2RX7LTA4HHPGDSIL2 | |
| SCHEMBL10317579 | 0.71 | NPC1 (0.51) | P2RX7LTA4HHPGDSIL2ALDH1A1 | |
| SCHEMBL4764672 | 0.71 | LTA4H (0.42) | P2RX7LTA4HHPGDSIL2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8623871-B2 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-1998612-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007087442-A2 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254363-A1 | Substituted biaryl compounds for inflammation and immune-related uses | CCR1, CCR3, CXCR2 | P2RX7 257/4885LTA4H 122/4885HPGDS 738/4885 |
| US-20140121217-A1 | SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CCR3, CXCR2 | P2RX7 257/4885LTA4H 122/4885HPGDS 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.